Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,944.37 +891.14 (+1.41%) CMC Crypto 200
1,347.66 -48.87 (-3.50%)
BrightSpring Health Services, Inc. (BTSG)
After hours:
| Previous close | 10.41 |
| Open | 10.40 |
| Bid | 10.56 x 800 |
| Ask | 10.61 x 400 |
| Day's range | 10.31 - 10.65 |
| 52-week range | 7.85 - 12.14 |
| Volume | |
| Avg. volume | 2,183,426 |
| Market cap | 1.811B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.68 |
GlobeNewswireBrightSpring Health Services, Inc. Welcomes Timothy A. Wicks to Board of Directors
LOUISVILLE, Ky., April 26, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced that on April 24, 2024, BrightSpring appointed Timothy A. Wicks as a new member of the Board of Directors. Mr. Wicks will assume his new role effective immediately, bringing the Company’s total Board of Directors to seven members, including two independent di
Simply Wall St.While public companies own 20% of BrightSpring Health Services, Inc. (NASDAQ:BTSG), private equity firms are its largest shareholders with 48% ownership
Key Insights BrightSpring Health Services' significant private equity firms ownership suggests that the key decisions...
- GlobeNewswire
BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®
LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are exp
